PALO ALTO, Calif., Dec. 21, 2010 /PRNewswire/ — Jazz
Pharmaceuticals, Inc. (Nasdaq:
JAZZ) today announced that the United States Patent and
Trademark Office (USPTO) has issued a patent related to Xyrem®
(sodium oxybate) oral solution titled “Microbiologically Sound and
Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of
Narcolepsy.” The new patent, number 7,851,506, is also listed
in the FDA’s Approved Drug Products List (the Orange Book).
In addition to the newly issued patent, Xyrem is protected by
seven other patents related to the product’s formulation and Jazz
Pharmaceuticals’ distribution system. Six issued patents are
now listed in the Orange Book. These patents expire from 2019
to 2024.
“Enhancing and enforcing the intellectual property coverage for
Xyrem is an important strategic priority for our company,” said
Bruce Cozadd, chairman and chief executive officer of Jazz
Pharmaceuticals.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is a specialty pharmaceutical company
focused on identifying, developing and commercializing innovative
products to meet unmet medical needs in neurology and psychiatry.
For further information see www.JazzPharmaceuticals.com.
“Safe Harbor” Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements,
including, but not limited to, Jazz Pharmaceuticals’ intent to
vigorously enforce its intellectual property rights. These
forward-looking statements are based on the company’s current
expectations and inherently involve significant risks and
uncertainties. Jazz Pharmaceuticals’ actual results could
differ materially from those anticipated in such forward looking
statements as a result of these risks and uncertainties, w
‘/>”/>
